TBX-3400
A NEW CLASS OF CELL THERAPY
Overview
-
Cell-based immunotherapy in clinical testing.
-
Indications: solid tumors and infectious disease.
-
.Target Dose: anticipated at 10 to 10 cells/kg
-
Treatment schedule: 2-week or 4-week schedule.
-
Manufacturing: a 4-hour process which yields up to 16 doses that can be cryopreserved.
6
7
Key Milestones
-
Phase I/II clinical trial for Stage 3 & 4 Melanoma.
-
Phase I/II clinical trial for solid tumors.
-
First-in-human Safety Study data approved by Japan’s MHLW.
-
US Orphan Drug Designation for Melanoma.
1. Blood Collection: blood is drawn from the patient in a hospital or clinic in an outpatient setting.
2. Processing: Immune cells are separated and the white blood cells are treated with TBX-4000 protein.
3. Treatment: the treated cells are then returned to the patient.
TREATING THE PATIENT
Greater Access to Patients
-
No longer need the patient to be present, only the patient’s cells.
-
Eliminates the toll on the patient of recurring blood draws.
-
Cells can be shipped around the world, processed, and sent back.
-
Regional Cell Processing Centers.
Significant Cost Savings
-
Cryopreservation reduces the number of manufacturing runs per patient.
-
The cost of manufacturing declines by over 75%.
-
Improved scheduling and logistics.
-
Makes cell therapies affordable.